277 related articles for article (PubMed ID: 36790005)
21. Comparison of CalliSpheres
Shi Z; Wang D; Kang T; Yi R; Cui L; Jiang H
Radiol Oncol; 2023 Mar; 57(1):70-79. PubMed ID: 36794998
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib versus DEB-TACE alone in treating huge hepatocellular carcinoma patients.
Li N; Chen J
Ir J Med Sci; 2022 Dec; 191(6):2611-2617. PubMed ID: 35083645
[TBL] [Abstract][Full Text] [Related]
23. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
24. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma.
Guo JH; Liu SX; Gao S; Kou FX; Zhang X; Wu D; Li XT; Chen H; Wang XD; Liu P; Zhang PJ; Xu HF; Cao G; Zhu LZ; Yang RJ; Zhu X
World J Gastroenterol; 2020 Jul; 26(27):3975-3988. PubMed ID: 32774071
[TBL] [Abstract][Full Text] [Related]
25. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of HepaSphere Drug-Eluting Bead Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy as the Second-Line Treatment in Advanced Hepatocellular Carcinoma.
Liu B; Gao S; Guo J; Kou F; Liu S; Zhang X; Feng A; Wang X; Cao G; Chen H; Liu P; Xu H; Gao Q; Yang R; Xu L; Zhu X
J Hepatocell Carcinoma; 2024; 11():477-488. PubMed ID: 38463543
[TBL] [Abstract][Full Text] [Related]
27. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
[TBL] [Abstract][Full Text] [Related]
28. Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis.
Schindler P; Kaldewey D; Rennebaum F; Trebicka J; Pascher A; Wildgruber M; Köhler M; Masthoff M
J Cancer Res Clin Oncol; 2024 May; 150(5):235. PubMed ID: 38710956
[TBL] [Abstract][Full Text] [Related]
29. Drug-eluting bead transarterial chemoembolization (DEB-TACE) versus conventional transarterial chemoembolization (cTACE) in colorectal liver metastasis: Efficacy, safety, and prognostic factors.
Zhang H; Wu C; Chen M; Sun Y; Han J
J Cancer Res Ther; 2023 Dec; 19(6):1525-1532. PubMed ID: 38156918
[TBL] [Abstract][Full Text] [Related]
30. Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma.
Zhao C; Ma SPZCY
J BUON; 2019; 24(3):1150-1166. PubMed ID: 31424674
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis.
Hu L; Lin J; Shi X; Wang A
World J Surg Oncol; 2023 Jul; 21(1):208. PubMed ID: 37475030
[TBL] [Abstract][Full Text] [Related]
32. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma.
Chiu SH; Chang PY; Shih YL; Huang WY; Ko KH; Chang WC; Huang GS
Drug Des Devel Ther; 2020; 14():5029-5041. PubMed ID: 33235441
[TBL] [Abstract][Full Text] [Related]
34. Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma.
Li B; Qiu J; Zheng Y; Shi Y; Zou R; He W; Yuan Y; Zhang Y; Wang C; Qiu Z; Li K; Zhong C; Yuan Y
Ann Surg Open; 2021 Jun; 2(2):e057. PubMed ID: 37636551
[TBL] [Abstract][Full Text] [Related]
35. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
36. Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenic trioxide for unresectable large or huge hepatocellular carcinoma: a prospective study.
Duan X; Li H; Chen P; Sun T; Kuang D; Lu H; Qiao B; Fan Z; Ren Z; Han X
Eur Radiol; 2024 Feb; 34(2):1258-1267. PubMed ID: 37581654
[TBL] [Abstract][Full Text] [Related]
37. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
38. Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
Yu B; Zhang N; Feng Y; Zhang Y; Zhang T; Wang L
J Hepatocell Carcinoma; 2023; 10():1735-1748. PubMed ID: 37822726
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients.
Lee IJ; Lee JH; Lee YB; Kim YJ; Yoon JH; Yin YH; Lee M; Hur S; Kim HC; Jae HJ; Chung JW
Ther Adv Med Oncol; 2019; 11():1758835919866072. PubMed ID: 31447948
[TBL] [Abstract][Full Text] [Related]
40. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
Megías Vericat JE; García Marcos R; López Briz E; Gómez Muñoz F; Ramos Ruiz J; Martínez Rodrigo JJ; Poveda Andrés JL
Radiologia; 2015; 57(6):496-504. PubMed ID: 25857250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]